![Iain Dukes](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Iain Dukes
Directeur Général chez
TRAWS PHARMA, INC.
Fortune : 340 926 $ au 31/05/2026
Profil
Le Dr Iain D. Dukes est directeur général de Viriom, Inc, président et directeur de Kartos Therapeutics, Inc, directeur indépendant d'Ikena Oncology, Inc, Venture Partner d'OrbiMed Advisors Private Equity, président d'Iovance Biotherapeutics, Inc, président exécutif de Theseus Pharmaceuticals, Inc, président de Telios Pharmaceuticals, Inc et président et directeur général d'Arrys Therapeutics, Inc. Il siège au conseil d'administration d'Angiex, Inc, ENYO Pharma SA, Kartos Therapeutics, Inc, Ikena Oncology, Inc, NeRRe Therapeutics Holdings Ltd, NeRRe Therapeutics Ltd et ReViral Ltd. Le Dr Dukes a été précédemment employé en tant que membre du conseil de surveillance par Themis Bioscience GmbH, SVP et responsable du développement commercial par Merck Research Laboratories Massachusetts LLC, VP Recherche et développement externe par Amgen, Inc, président et chef de la direction d'Essentialis, Inc, vice-président chargé des licences scientifiques et technologiques de GlaxoSmithKline, Inc, chef du développement exploratoire de Glaxo Wellcome, Inc, directeur de Glaxo, Inc, et premier vice-président chargé du développement commercial et des licences de Merck & Co. Il a également été membre du conseil d'administration de KaNDy Therapeutics Ltd. Il a obtenu un diplôme de premier cycle à l'université de Bath, un diplôme de premier cycle à l'université d'Oxford, un diplôme d'études supérieures à l'université de Leeds et un doctorat à l'université d'Oxford.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 15/04/2026 | 54 000 ( 0,01% ) | 221 400 $ | 31/05/2026 | |
TRAWS PHARMA, INC. 0,54% | 01/05/2026 | 81 867 ( 0,54% ) | 119 526 $ | 31/05/2026 |
Postes actifs de Iain Dukes
| Sociétés | Poste | Début |
|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. | Président | 16/08/2016 |
| TRAWS PHARMA, INC. | Directeur Général | 31/03/2025 |
Telios Pharmaceuticals, Inc.
 Telios Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Pharmaceuticals, research | Fondateur | - |
NeRRe Therapeutics Holdings Ltd.
 NeRRe Therapeutics Holdings Ltd. Miscellaneous Commercial ServicesCommercial Services Engages in research and development of biotechnology | Directeur/Membre du Conseil | 08/09/2017 |
Trawsfynydd Therapeutics, Inc.
 Trawsfynydd Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Engages in discovering and developing antiviral medicines | Fondateur | 01/01/2021 |
Feldan Bio, Inc.
 Feldan Bio, Inc. Pharmaceuticals: MajorHealth Technology Develops, produces and supplies recombinant proteins for therapeutic and research purposes | Directeur/Membre du Conseil | - |
Lomond Therapeutics, Inc.
 Lomond Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as biopharmaceutical company for treating hematological cancers | Directeur Général | - |
Venetian-1 Acquisition Corp.
 Venetian-1 Acquisition Corp. Pharmaceuticals: MajorHealth Technology Develops medicines for hematological malignancies | Directeur Général | 01/11/2024 |
Viriom, Inc.
 Viriom, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology company | Directeur Général | 01/02/2019 |
Anciens postes connus de Iain Dukes
| Sociétés | Poste | Fin |
|---|---|---|
| ░░░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░ ░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░ | - |
| ░░░░░░ ░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░ ░░░░░░░░ ░░░░░░░░░░░░ ░░░░░░░░░░░░░ ░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Formation de Iain Dukes
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
55
Relations au 1er degré
33
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 33 |
|---|---|
Amgen, Inc.
 Amgen, Inc. BiotechnologyHealth Technology Discovers, develops, manufactures and delivers human therapeutics | Health Technology |
Merck & Co., Inc.
 Merck & Co., Inc. Pharmaceuticals: MajorHealth Technology Manufactures human and animal health pharmaceutical products & vaccines | Health Technology |
Telios Pharmaceuticals, Inc.
Telios Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Pharmaceuticals, research | Health Technology |
Traws Pharma, Inc.
 Traws Pharma, Inc. BiotechnologyHealth Technology Discovers and develops products for patients with cancer | Health Technology |
University of Bath
 University of Bath Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Oxford
 University of Oxford Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Leeds
 University of Leeds Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
GlaxoSmithKline, Inc.
 GlaxoSmithKline, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets pharmaceutical products | Health Technology |
Merck Research Laboratories Massachusetts LLC
 Merck Research Laboratories Massachusetts LLC Pharmaceuticals: MajorHealth Technology Discovers, develops, and markets a broad range of human and animal health products | Health Technology |
OrbiMed Advisors Private Equity
 OrbiMed Advisors Private Equity Investment ManagersFinance OrbiMed Advisors Private Equity invests in companies located across the globe primarily in North America, Asia, Europe and Israel. The firm focuses on biopharmaceuticals, medical technology and healthcare services. It participates in seed-stage, early stage, growth transactions. It also provides debt capital and monetize royalty streams and invests in publicly-traded companies. | Finance |
Essentialis, Inc.
 Essentialis, Inc. Pharmaceuticals: OtherHealth Technology Develops therapeutic products in curing metabolic diseases | Health Technology |
Glaxo Wellcome, Inc.
 Glaxo Wellcome, Inc. Pharmaceuticals: MajorHealth Technology Engages in pharmaceutical preparations | Health Technology |
Glaxo, Inc. | |
Themis Bioscience GmbH
 Themis Bioscience GmbH Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company that develops vaccines to prevent infectious diseases | Health Technology |
Iovance Biotherapeutics, Inc.
 Iovance Biotherapeutics, Inc. BiotechnologyHealth Technology Develops biotechnological products for the treatment of cancer | Health Technology |
BITOECH Consulting SAS
 BITOECH Consulting SAS Miscellaneous Commercial ServicesCommercial Services Provides business consulting services | Commercial Services |
NeRRe Therapeutics Ltd.
 NeRRe Therapeutics Ltd. Medical DistributorsDistribution Services Provides clinical and pre clinical drugs for treatment of neuronal hypersensitivity | Distribution Services |
Feldan Bio, Inc.
Feldan Bio, Inc. Pharmaceuticals: MajorHealth Technology Develops, produces and supplies recombinant proteins for therapeutic and research purposes | Health Technology |
ENYO Pharma SA
 ENYO Pharma SA BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company | Health Technology |
ReViral Ltd.
 ReViral Ltd. BiotechnologyHealth Technology Develops novel antiviral therapeutics | Health Technology |
Ikena Oncology, Inc.
 Ikena Oncology, Inc. BiotechnologyHealth Technology Develops metabolic enzymes based immunotherapy for oncology applications | Health Technology |
Angiex, Inc.
 Angiex, Inc. Miscellaneous Commercial ServicesCommercial Services Develops vascular-targeted biotherapeutics designed for the treatment of solid cancers and other diseases of pathological angiogenesis | Commercial Services |
KaNDy Therapeutics Ltd.
 KaNDy Therapeutics Ltd. BiotechnologyHealth Technology Develops medicines for female sex hormone disorders | Health Technology |
Arrys Therapeutics, Inc.
 Arrys Therapeutics, Inc. Hospital/Nursing ManagementHealth Services Provides treatments to cancer patients | Health Services |
Theseus Pharmaceuticals, Inc.
 Theseus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops and supplies drugs for cancer patients | Health Technology |
Kartos Therapeutics, Inc.
 Kartos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as clinical stage biopharmaceutical company | Health Technology |
Viriom, Inc.
Viriom, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology company | Commercial Services |
NeRRe Therapeutics Holdings Ltd.
NeRRe Therapeutics Holdings Ltd. Miscellaneous Commercial ServicesCommercial Services Engages in research and development of biotechnology | Commercial Services |
Lomond Therapeutics, Inc.
Lomond Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as biopharmaceutical company for treating hematological cancers | Health Technology |
Gwynant Therapeutics
 Gwynant Therapeutics Pharmaceuticals: MajorHealth Technology Develops novel small molecules for oncology targets | Health Technology |
Venetian-1 Acquisition Corp.
Venetian-1 Acquisition Corp. Pharmaceuticals: MajorHealth Technology Develops medicines for hematological malignancies | Health Technology |
Trawsfynydd Therapeutics, Inc.
Trawsfynydd Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Engages in discovering and developing antiviral medicines | Commercial Services |
Eilean Therapeutics LLC
 Eilean Therapeutics LLC Pharmaceuticals: MajorHealth Technology Engages in discovery and development of small molecule inhibitors therapies for hematological cancers | Health Technology |
